← Back to Screener
Treace Medical Concepts, Inc. Common Stock (TMCI)
Price$1.87
Favorite Metrics
Price vs S&P 500 (26W)-67.78%
Price vs S&P 500 (4W)59.36%
Market Capitalization$144.04M
All Metrics
Book Value / Share (Quarterly)$1.36
P/TBV (Annual)1.95x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)14.47%
Cash Flow / Share (Quarterly)$-0.46
Price vs S&P 500 (YTD)-11.62%
Gross Margin (TTM)79.81%
Net Profit Margin (TTM)-27.74%
EPS (TTM)$-0.93
10-Day Avg Trading Volume1.58M
EPS Excl Extra (TTM)$-0.93
Revenue Growth (5Y)29.95%
EPS (Annual)$-0.93
ROI (Annual)-41.28%
Gross Margin (Annual)79.81%
Net Profit Margin (5Y Avg)-26.57%
Cash / Share (Quarterly)$0.76
Revenue Growth QoQ (YoY)-9.01%
ROA (Last FY)-30.96%
Revenue Growth TTM (YoY)1.59%
EBITD / Share (TTM)$-0.72
ROE (5Y Avg)-49.14%
Operating Margin (TTM)-26.75%
Cash Flow / Share (Annual)$-0.46
P/B Ratio1.65x
P/B Ratio (Quarterly)1.79x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.89x
Net Interest Coverage (TTM)-22.20x
ROA (TTM)-29.52%
EPS Incl Extra (Annual)$-0.93
Current Ratio (Annual)4.31x
Quick Ratio (Quarterly)2.95x
3-Month Avg Trading Volume0.88M
52-Week Price Return-67.01%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.25
P/S Ratio (Annual)0.68x
Asset Turnover (Annual)1.12x
52-Week High$7.78
Operating Margin (5Y Avg)-25.25%
EPS Excl Extra (Annual)$-0.93
CapEx CAGR (5Y)66.07%
26-Week Price Return-63.80%
Quick Ratio (Annual)2.95x
13-Week Price Return-20.36%
Total Debt / Equity (Annual)0.64x
Current Ratio (Quarterly)4.31x
Enterprise Value$188.912
Revenue / Share Growth (5Y)24.22%
Asset Turnover (TTM)1.06x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.14x
Pretax Margin (Annual)-27.74%
Cash / Share (Annual)$0.76
3-Month Return Std Dev94.53%
Gross Margin (5Y Avg)80.63%
Net Income / Employee (TTM)$-0
ROE (Last FY)-67.56%
Net Interest Coverage (Annual)-22.20x
EPS Basic Excl Extra (Annual)$-0.93
Receivables Turnover (TTM)5.13x
Total Debt / Equity (Quarterly)0.64x
EPS Incl Extra (TTM)$-0.93
Receivables Turnover (Annual)5.13x
ROI (TTM)-39.44%
P/S Ratio (TTM)0.68x
Pretax Margin (5Y Avg)-26.57%
Revenue / Share (Annual)$3.36
Tangible BV / Share (Annual)$1.25
Price vs S&P 500 (52W)-96.84%
Year-to-Date Return-8.98%
5-Day Price Return45.75%
EPS Normalized (Annual)$-0.93
ROA (5Y Avg)-23.57%
Net Profit Margin (Annual)-27.74%
Month-to-Date Return66.42%
Cash Flow / Share (TTM)$-0.73
EBITD / Share (Annual)$-0.72
Operating Margin (Annual)-26.75%
LT Debt / Equity (Annual)0.64x
ROI (5Y Avg)-31.08%
LT Debt / Equity (Quarterly)0.64x
EPS Basic Excl Extra (TTM)$-0.93
P/TBV (Quarterly)1.95x
P/B Ratio (Annual)1.79x
Inventory Turnover (TTM)1.14x
Pretax Margin (TTM)-27.74%
Book Value / Share (Annual)$1.36
Price vs S&P 500 (13W)-21.04%
Beta1.23x
Revenue / Share (TTM)$3.33
ROE (TTM)-62.19%
52-Week Low$1.17
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.55
2.55
2.55
2.50
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
TMCITreace Medical Concepts, Inc. Common Stock | 0.68x | 29.95% | 79.81% | -26.75% | $1.87 |
SYKStryker Corporation | 5.15x | 11.84% | 64.57% | 19.43% | $338.38 |
BSXBoston Scientific Corp. | 4.76x | 15.16% | 69.01% | 18.00% | $63.42 |
MMM3M Company | 3.18x | -4.97% | 39.92% | 18.55% | $150.55 |
MDLNMedline Inc. Class A common stock | 2.21x | — | 26.44% | 7.78% | $46.94 |
BDXBecton, Dickinson and Co. | 2.01x | 6.32% | 46.42% | 12.15% | $154.82 |
RMDResMed Inc. | 6.06x | 11.72% | 60.85% | 33.70% | $224.72 |
DXCMDexCom, Inc. | 5.23x | 19.33% | 62.09% | 19.56% | $61.23 |
WSTWest Pharmaceutical Services, Inc. | 6.22x | 7.44% | 35.91% | 19.03% | $269.81 |
PODDInsulet Corporation | 5.31x | 24.53% | 71.63% | 12.92% | $201.47 |
PENPenumbra, Inc. | 9.31x | 20.16% | 67.14% | 13.48% | $331.47 |
About
Treace Medical Concepts develops and commercializes the Lapiplasty 3D Bunion Correction procedure, a patented surgical solution for treating bunion deformities. The procedure addresses the underlying cause of bunions across all planes of deformity while enabling patients to return to normal activities quickly. The company markets its devices to surgeons, ambulatory surgery centers, and hospitals in the large and growing orthopedic foot surgery market.